

# Renumbered Claims

10/054,712  
APBI-P08-317

## IN THE CLAIMS:

Please cancel, without prejudice, claims 1-10 and 12-35 which were previously withdrawn from consideration as directed to a nonelected invention.

1-10. (Cancelled)

11. (Previously presented) A recombinant chimeric protein comprising at least one ligand-binding domain which binds to a selected ligand and an action domain which is heterologous with respect to the ligand-binding domain, wherein the selected ligand binds to the ligand-binding domain and to a ligand-binding domain of another protein to form a ligand cross-linked complex with the two protein molecules, and further has one or more of the following characteristics:

- (i) the ligand is not a protein;
- (ii) the ligand has a molecular weight less than 5 kD; and
- (iii) the ligand is membrane permeable; and

wherein the action domain induces apoptosis in a cell following formation of the ligand cross-linked complex.

12-35. (Cancelled)

36. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein comprises two or more ligand-binding domains.

37. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein comprises at least one ligand-binding domain which binds to a ligand having a molecular weight less than 3 kD.

38. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein comprises at least one ligand-binding domain having between 50 and 350 amino acid residues.

39. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein

comprises at least one naturally-occurring ligand binding domain.

40. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein comprises at least one ligand-binding domain comprising a non-naturally-occurring peptide sequence.

41. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein binds to the selected ligand with a  $K_D$  value less than or equal to about  $10^{-6}$  M.

42. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein comprises at least one ligand binding domain comprising an immunophilin domain.

43. (Previously presented) The chimeric protein of claim 11, wherein the chimeric protein comprises at least one ligand-binding domain which binds to FK506, FK520, or derivatives thereof.

44. (Previously presented) The chimeric protein of claim 11, wherein the action domain comprises a cytoplasmic portion of a Fas or TNF receptor sufficient to induce apoptosis in a cell following formation of the ligand cross-linked complex.

45. (Previously presented) The chimeric protein of claim 11, wherein the action domain comprises a cytoplasmic domain of a receptor which induces apoptosis.

46. (Previously presented) The chimeric protein of claim 11, wherein said ligand is a synthetic organic molecule having a molecular weight of less than 5 kDa.